<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.7.3" -->
<rss version="2.0"
	xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>Sedative Related Disorders</title>
		<description><![CDATA[Behavioral Health Central - Articles and Resources for the Behavioral Healthcare Industry.]]></description>
		<link>http://behavioralhealthcentral.com/</link>
		<lastBuildDate>Tue, 16 Mar 2010 19:59:01 +0000</lastBuildDate>
        <generator>FeedCreator 1.7.3</generator>
		<image>
			<url>http://behavioralhealthcentral.com/images/M_images/joomla_rss.png</url>
			<title>Sedative Related Disorders</title>
			<link>http://behavioralhealthcentral.com/</link>
			<description>Behavioral Health Central - Articles and Resources for the Behavioral Healthcare Industry.</description>
		</image>
		<item>
			<title>Sedative-Hypnotic Medication Exposures and Poisonings in Izmir, Turkey </title>
			<link>http://behavioralhealthcentral.com/index.php/20090522235/Sedative-latest/sedative-hypnotic-medication-exposures-and-poisonings-in-izmir-turkey.html?Itemid=</link>
			<guid>http://behavioralhealthcentral.com/index.php/20090522235/Sedative-latest/sedative-hypnotic-medication-exposures-and-poisonings-in-izmir-turkey.html?Itemid=</guid>
			<description><![CDATA[<span id="dnn_ctr1408_ViewBHC_Article_lblArticleDetails">By Oray N.C.;  Hocaoglu N.;  Oray D.;  Demir O.;  Atilla R.;  Tuncok Y.<br /><br /> The aim of this study was to analyse intoxications concerning sedative-hypnotic medication patients admitted to the Department of Emergency Medicine in Dokuz Eylul University Hospital (EMDEU) between 1993 and 2005. Demographics of the patients, characteristics of sedative-hypnotic exposures, performed treatment attempts and outcome of the poisoned patients were recorded on standard data forms that were later entered into a computerized database programme. Related to the sedative-hypnotic exposures, 686 poisoning cases were admitted to the EMDEU. Mean age was 10.8 Ã‚± 6.5 years among the paediatric age group (&lt;17 years old, 169, 24.6%) and 30.3 Ã‚± 12.8 years among the adult group (&gt;17 years old, 509, 74.2%). The most common sedative-hypnotic agents were benzodiazepines (286, 35.8%), alprazolam accounted for 41.6% of them (119). Most of the patients admitted to EMDEU...]]></description>
		<dc:creator>Administrator</dc:creator>
			<pubDate>Fri, 22 May 2009 12:54:04 +0000</pubDate>
		</item>
		<item>
			<title>Mass spectrometric approaches in impaired driving toxicology </title>
			<link>http://behavioralhealthcentral.com/index.php/20090522234/Sedative-latest/mass-spectrometric-approaches-in-impaired-driving-toxicology.html?Itemid=</link>
			<guid>http://behavioralhealthcentral.com/index.php/20090522234/Sedative-latest/mass-spectrometric-approaches-in-impaired-driving-toxicology.html?Itemid=</guid>
			<description><![CDATA[<span id="dnn_ctr1408_ViewBHC_Article_lblArticleDetails">By Maurer H.H.<br /><br /> Driving under the influence of prescribed or illegal drugs increases the risk of having road accidents, just like driving under the influence of alcohol.<br /> <br /> In forensic toxicology, an increasing number of blood samples must be analyzed for drugs. Immunoassays tailored for a limited number of drugs (of abuse) are usually applied as prescreening tests at the roadside and/or in the laboratory. However, many other common drugs, such as anesthetics, antidepressants, antiepileptics, antihistamines, newer designer drugs, herbal drugs, neuroleptics (antipsychotics), opioids, or sedative-hypnotics, can also impair drivers. Therefore, this paper reviews multianalyte single-stage and tandem gas or liquid chromatography-mass spectrometry (GC-MS or LC-MS) procedures for the screening, identification, and validated quantification of such drugs in blood that have been reported since 2003. <br /> <br /> Basic information about the biosample assayed, workup, chromatography, the mass spectral detection mode, and validation data...]]></description>
		<dc:creator>Administrator</dc:creator>
			<pubDate>Fri, 22 May 2009 12:53:14 +0000</pubDate>
		</item>
		<item>
			<title>Stress tied to substance use among veterinarians</title>
			<link>http://behavioralhealthcentral.com/index.php/20090522233/Sedative-latest/stress-tied-to-substance-use-among-veterinarians.html?Itemid=</link>
			<guid>http://behavioralhealthcentral.com/index.php/20090522233/Sedative-latest/stress-tied-to-substance-use-among-veterinarians.html?Itemid=</guid>
			<description><![CDATA[<span id="dnn_ctr1408_ViewBHC_Article_lblArticleDetails">By Amy Norton<br /><br />
<p><a target="_blank" href="http://www.reuters.com/"> <img alt="Reuters" style="margin-bottom: 5px;" src="http://behavioralhealthcentral.com/Portals/0/logo_reuters.gif" border="0" width="164" height="60" />  </a> <br /><span style="font-size: 10px;">Copyright 2008 Thomson Reuters.<br /><a href="http://behavioralhealthcentral.com/ClinicalCorner/SubstanceRelatedDisorders/Sedative/tabid/233/Default.aspx?ArticleId=17968&amp;PageNumber=1#full">Click for restrictions</a> .</span></p>
"
<p class="datestamp"><small><em><span style="font-size: 10pt;">Last Updated: 2009-03-06 11:28:47 -0400 (Reuters Health)</span></em></small></p>
<p class="byline">NEW YORK (Reuters Health) - High job stress may cause some veterinarians to turn to heavy drinking, smoking or medication to cope, a German study indicates.</p>
<p>In a survey of more than 2,000 veterinarians in Germany, the researchers found that 8 percent reported intense psychosocial stress, while another 45 percent said they had intermediate stress.</p>
<p>The team found that those under heavy stress were more likely than their counterparts to binge-drink or regularly use medications like painkillers and sedatives.</p>
<p>In addition, highly stressed vets were more likely to say they often felt demoralized -- which, in turn, was linked to greater risks of problem drinking, smoking and chronic medication use.</p>
<p>The findings, published online in the Journal of Occupational Medicine &amp; Toxicology, suggest that some vets turn to substance use...]]></description>
		<dc:creator>Administrator</dc:creator>
			<pubDate>Fri, 22 May 2009 12:52:08 +0000</pubDate>
		</item>
		<item>
			<title>Sedative-Hypnotic Medication Exposures and Poisonings in Izmir, Turkey</title>
			<link>http://behavioralhealthcentral.com/index.php/?Itemid=</link>
			<guid>http://behavioralhealthcentral.com/index.php/?Itemid=</guid>
			<description><![CDATA[The aim of this study was to analyse intoxications concerning sedative-hypnotic medication patients admitted to the Department of Emergency Medicine in Dokuz Eylul University Hospital (EMDEU) between 1993 and 2005. Demographics of the patients, characteristics of sedative-hypnotic exposures, performed treatment attempts and outcome of the poisoned patients were recorded on standard data forms that were later entered into a computerized database programme. Related to the sedative-hypnotic exposures, 686 poisoning cases were admitted to the EMDEU. Mean age was 10.8 &plusmn; 6.5 years among the paediatric age group (<17 years old, 169, 24.6%) and 30.3 &plusmn; 12.8 years among the adult group (>17 years old, 509, 74.2%). The most common sedative-hypnotic agents were benzodiazepines (286, 35.8%), alprazolam accounted for 41.6% of them (119). Most of the patients admitted to EMDEU were asymptomatic (61.7%). Observation alone was recommended in 53.9% of EMDEU cases. Although prescription of benzodiazepines is restricted, benzodiazepine was the...]]></description>
		<dc:creator>Administrator</dc:creator>
		</item>
		<item>
			<title>Indiplon: A nonbenzodiazepine sedative-hypnotic for the treatment of insomnia</title>
			<link>http://behavioralhealthcentral.com/index.php/?Itemid=</link>
			<guid>http://behavioralhealthcentral.com/index.php/?Itemid=</guid>
			<description><![CDATA[OBJECTIVE: To review the pharmacology, pharmacokinetics, pharmacodynamics, efficacy data, and adverse effects of indiplon in the treatment of transient and chronic insomnia in adult and geriatric patients. <br /><br /><br /><br />DATA SOURCES: A literature search was conducted using MEDLINE (1966-May 2008), International Pharmaceutical Abstracts (1970-May 2008), and Cochrane database (2007) for the key words indiplon or NBI-34060. References cited in the articles were reviewed for additional information. Abstract data were included only in the absence of significant published data. <br /><br /><br /><br />STUDY SELECTION AND DATA EXTRACTION: English-language literature reporting animal and human clinical studies was reviewed to evaluate data on the pharmacology, pharmacokinetics, pharmacodynamics, efficacy, and adverse effects of indiplon. Clinical trials selected for inclusion were limited to those with human subjects, with the accepted inclusion of pharmacology data in animals. <br /><br /><br /><br />DATA SYNTHESIS: Indiplon is a nonbenzodiazepine sedative-hypnotic that exhibits its sedating activity...]]></description>
		<dc:creator>Administrator</dc:creator>
		</item>
		<item>
			<title>Withdrawal Symptoms in Critically Ill Children After Long-Term Administration of Sedatives ...</title>
			<link>http://behavioralhealthcentral.com/index.php/?Itemid=</link>
			<guid>http://behavioralhealthcentral.com/index.php/?Itemid=</guid>
			<description><![CDATA[OBJECTIVE: To establish frequencies of benzodiazepine and opioid withdrawal symptoms, and correlations with total doses and duration of administration. <br /><br /><br /><br />DESIGN: A prospective, repeated-measures design. <br /><br /><br /><br />SETTING: Two pediatric intensive care units in a university children's hospital. <br /><br /><br /><br />PATIENTS: Seventy-nine children, aged 0 days to 16 yrs, who received intravenous midazolam and/or opioids for >5 days. <br /><br /><br /><br />INTERVENTIONS: None. <br /><br /><br /><br />MEASUREMENTS AND MAIN RESULTS: Pediatric intensive care unit nurses assessed withdrawal symptoms using the Sophia Benzodiazepine and Opioid Withdrawal Checklist, which includes all withdrawal symptoms (n = 24) described in the pediatric literature. Over 6 months, 2188 observations in 79 children were recorded. Forty-two percent of observations were performed within 24 hrs after tapering off or discontinuation of medication. Symptoms representing overstimulation of the central nervous system, such as anxiety, agitation, grimacing, sleep disturbance, increased...]]></description>
		<dc:creator>Administrator</dc:creator>
		</item>
	</channel>
</rss>
